Since amplification or mutation of oncogenes is less common in early-stage prostate tumor, genomic rearrangements might comprise a significant method of cancer gene dysregulation in nascent tumors

Since amplification or mutation of oncogenes is less common in early-stage prostate tumor, genomic rearrangements might comprise a significant method of cancer gene dysregulation in nascent tumors. Full sequencing of prostate cancer genomes has provided additional insight into chromosomal rearrangements